Agilent Technologies (A)
Health Care · Life Sciences Tools & Services · NYSE
Agilent Technologies provides essential laboratory instruments, software, and services that power scientific discovery and clinical diagnostics.
What Agilent Technologies does
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides a broad range of instruments, software, services, and consumables used for laboratory workflows, encompassing areas such as liquid and gas chromatography, mass spectrometry, and cell analysis. Agilent serves customers across the pharmaceutical, biotechnology, clinical, environmental, and forensic research industries.
Themes: life sciences research, clinical diagnostics, laboratory automation, genomics and proteomics, mass spectrometry, analytical chemistry
Fundamentals
- Price$168.17 as of 2026-10-08 close
- Market cap$47.4B as of 2026-08-26 (share count; price 2026-10-08)
- 1-year return+19.4% 2025-10-08 close $140.81 → 2026-10-08 close $168.17
- P/E33.81 as of 2026-10-08
- Net margin+18.8% FY2025, SEC XBRL
- ROE+19.3% FY2025, SEC XBRL
- Debt / equity0.47 as of 2026-09-03
- Revenue growth (YoY)+9.1% as of 2026-09-03
- Revenue CAGR (3y)+0.5% SEC XBRL
- Beta0.96 as of 2026-09-03
- Last reported earnings2026-08-26 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.7%; 11-year non-decreasing per-share dividend streak (SEC XBRL).
How A compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
A is not currently in any published Top 10 list. Its scores are below.
Top 10 score
60.5 #216 of 1,379 scored · #29 of 151 in Health Care
Trend 80th (a strong uptrend, with buyers in control) and capital return 76th (consecutive years of dividend increases 11 years, net share count bought back over the year 2.1); weakest is growth (36th, 3-year revenue CAGR 0.5%, revenue growth year over year 9.1%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, A's dividend was covered by reported results (earnings payout 22%, free-cash-flow payout 24%). This describes past coverage, not a forecast.
- Earnings payout22% dividends / net income
- Free-cash-flow payout24% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Agilent Technologies looks technically
Agilent Technologies (A) is trading 25.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 25.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +25.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $154.94 | $154.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $133.53 | $133.53 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 177.05. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave upward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 47 trading days ago — a "golden cross", a bullish long-term signal | 47 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control | 39.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($157.08 to $177.05) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 55.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $177.05 | $177.05 |
|---|---|---|
| From the 52-week high | it is 5.0% below its 52-week high (its highest price of the past year) | -5.0% |
| Above the 52-week low | it is 55.2% above its 52-week low (its lowest price of the past year) | +55.2% |
| Below the 52-week high | it is 5.0% below its highest point of the past year | 5.0% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $179.57 (set on 2021-09-03) | $179.57 |
| Given back of the 52-week move | over the past year its closes ranged ($110.24 to $175.21), and it has given back only a small part of its rise from last year’s low — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $132.98 to $135.06. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.8% |
| From the all-time high | it is 6.3% below its all-time high | -6.3% |
| Nearest price level | it is trading 8.8% above a support level at $153.42 — a price it turned at three times since 2025-01-22, most recently on 2025-11-12. Since 2024-10-08 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.8% |
| All-time low | its lowest closing price on record is $8.60 (set on 2009-03-06) | $8.60 |
| Above the all-time low | it is 1855.9% above its all-time low | +1,856% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.15 between its high and its low — about 3.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.15 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $146.22 and $182.34 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $146.22 – $164.28 – $182.34 |
| Typical daily range (% of price) | its price moves about 3.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.1% |
| Stretch from the 200-day average | it is trading 6.7 daily ranges above its 200-day average price (25.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.07× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.1% since the prior reading | -0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.04 toward sell |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.9% |
|---|---|---|
| Open gap | it gapped 4.4% above the previous close 54 sessions ago and has not traded back through the level it left behind at 133.46 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.3% |
| Gap filled | a 2.8% gap up opened on 2026-08-27 has been "filled" 28 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 28 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -1.82% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.5 percentage points (the stock gained 14.5% while the market gained 1.0%) | +13.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 26.5 percentage points (the stock gained 30.3% while the market gained 3.8%) | +26.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.0 percentage points (the stock gained 46.4% while the market gained 17.5%) | +29.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.5 percentage points (the stock gained 19.4% while the market gained 15.0%) | +4.5% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.2% of the share price. | +9.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $134.98 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +24.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-26 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $160.06 — a volume-weighted average of daily closes over 31 sessions, not a true tick-by-tick VWAP. | +5.1% |
Price levels it has turned at before
A last closed at $168.17 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $153.42 | Support | 8.8% below the last close | turned there three times · 2025-01-22 to 2025-11-12 |
| $149.94 | Support | 10.8% below the last close | turned there three times · 2025-10-21 to 2026-08-11 |
| $145.78 | Support | 13.3% below the last close | turned there twice · 2024-10-15 to 2024-12-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $177.05.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close below $163.75.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.82 mean, 1=Strong Buy…5=Strong Sell) — 20 analysts
- Mean price target$175.20 range $155.00 – $190.00; median $177.50
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for A
- Consensus EPS estimate$1.72 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.00232 (-0.1%) from $1.73, on 2026-09-03, 31-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on global economic conditions and government funding for research institutions.","Risks associated with acquisitions, including integration challenges and the ability to realize expected synergies.","Supply chain dependencies for specialized components and raw materials."]
What changed in the latest 10-Q
AI-assisted comparison of A's 10-Q filed 2026-09-01 against the prior one filed 2026-06-01.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds 'Acquisition of Biocare' section stating acquisition completed on June 24, 2026 for net consideration paid of $950 million, with Biocare results included from acquisition date.
- Newer filing adds '2032 Senior Notes' section stating $600 million aggregate principal amount of senior notes issued June 25, 2026 at 99.968% of principal, maturing January 15, 2032, bearing 4.90% fixed interest per annum, payable semi-annually in arrears with payments commencing January 15, 2027.
- Newer filing adds 'Applied Markets segment' revenue section header appearing truncated at end of provided text.
- Removed:
- Older filing contains 'Pending Acquisition' section describing March 6, 2026 definitive agreement to acquire Biocare for approximately $950 million, subject to legal/regulatory approvals and customary closing conditions, with close expected in third quarter or no later than end of fiscal year 2026.
- Older filing includes 'Applied Markets segment' revenue figures for three and six months ended April 30, 2026 (increased 14 percent and 10 percent with 3 percentage point favorable currency impact in both periods).
- Reworded:
- Tariff recoverability language updated: older filing states 'We will assess the recoverability of these tariffs and will account for any such refunds by applying the gain contingency model. As of April 30, 2026, no refund receivable has been recorded.' Newer filing states 'Management continues to assess the recoverability of tariffs paid and will continue to recognize any recoveries in accordance with the gain contingency model when it is realized or realizable upon formal acceptance of refund claims submitted.'
- Tariff mitigation periods changed from 'three and six months ended April 30, 2026' (older) to 'three and nine months ended July 31, 2026' (newer), and wording changed from 'continued mitigation strategies' to 'continued strategies'.
- Middle East conflict description changed from 'The recent escalation of geopolitical tensions' and 'As the situation is rapidly changing, we will continue to monitor the potential impact that this conflict may have on our business' (older) to 'The continued geopolitical tensions' and 'As the situation remains dynamic, we continue to monitor the potential impact that such geopolitical tensions may have on our business' (newer).
- Middle East conflict result period changed from 'through the second quarter of fiscal year 2026' (older) to 'through the third quarter of fiscal year 2026' (newer).
- Net revenue figures and periods updated: older filing reports $1,835 million and $3,633 million for three and six months ended April 30, 2026 with increases of 10% and 8%, currency impacts of 4 and 3 percentage points favorable; newer filing reports $1,878 million and $5,511 million for three and nine months ended July 31, 2026 with increases of 8% for both periods, currency impacts of no impact and 2 percentage points favorable.
- Life Sciences and Diagnostics Markets segment revenue updated: older reports 12% and 8% increases for three and six months ended April 30, 2026 with 3 and 2 percentage point favorable currency impacts; newer reports 11% and 9% increases for three and nine months ended July 31, 2026 with no currency impact and 2 percentage point favorable impact.
- Agilent CrossLab segment revenue updated: older reports 6% and 8% increases for three and six months ended April 30, 2026 with 4 percentage point favorable currency impact in both periods; newer reports 6% and 7% increases for three and nine months ended July 31, 2026 with 1 and 2 percentage point favorable impacts.
- Basis of Presentation punctuation changed from 'Our fiscal year end is October 31' (older) to 'Our fiscal year-end is October 31' (newer).
- Notes:
- Newer filing text appears truncated at 'Revenue generated by our Applied Markets segment for'—figures for the Applied Markets segment in the newer filing are not present in the provided text.
- Older filing text appears truncated within Net income discussion ending mid-sentence at 'compared to net income of $215 million and $533 million for the co'; newer filing text does not include a corresponding Net income paragraph in the provided excerpt.
Risk Factors
- Reworded:
- In the newer filing (2026-09-01), the foreign currency exchange rate impact on revenue growth changed from '3 percentage point favorable impact ... in the six months ended April 30, 2026' to '2 percentage point favorable impact ... in the nine months ended July 31, 2026'.
- Page numbering after the first risk factor changed from 52 in the older filing (2026-06-01) to 55 in the newer filing (2026-09-01).
- Page numbering after the international sales risk factor changed from 53 in the older filing (2026-06-01) to 56 in the newer filing (2026-09-01).
- Notes:
- The newer risk factors text is truncated at 'Without the timely introduction of new products, services and enhancements, our products and services may become technologically obsolete over time, in which case our' and the older text at '...may become technologically obsolete over time, in which case our', so any changes after this point could not be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($95972) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 2 sells ($312644) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about A's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 11 matched disclosures for A from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding A as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 46,618,689
- Reported value $6,195,591,332
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about A's institutional holders → See what each manager we track holds →
Short interest (FINRA)
A had 5,078,629 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
A had 1.80% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.54 days to cover at the same settlement.
- Reported short interest (shares) 5,078,629
- Short interest (% of shares outstanding) 1.80%
- Prior settlement (shares) 5,677,007
- Reported change -10.54%
- Days to cover (reported) 2.54
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Waters (WAT)
- PerkinElmer (PKI)
- Shimadzu Corporation
- Bruker (BRKR)
- Revvity (RVTY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare A vs…
Agilent Technologies is found in…
Frequently asked questions
What does Agilent Technologies (A) do?
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides a broad range of instruments, software, services, and consumables used for laboratory workflows, encompassing areas such as liquid and gas chromatography, mass spectrometry, and cell analysis. Agilent serves customers across the pharmaceutical, biotechnology, clinical, environmental, and forensic research industries.
What sector is Agilent Technologies (A) in?
Agilent Technologies (A) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NYSE.
Does A pay a dividend?
Yes — Agilent Technologies (A) pays a dividend, with an indicated yield of about 0.66% and 11-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Agilent Technologies's (A) competitors?
Notable peers of Agilent Technologies (A) include Thermo Fisher Scientific, Danaher, Waters, PerkinElmer and Shimadzu Corporation. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in A?
Yes — we hold 11 matched STOCK Act disclosures for A from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Agilent Technologies (A) overbought or oversold right now?
Agilent Technologies (A) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on A come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.